⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PLRX News
Pliant Therapeutics, Inc. Common Stock
RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
prnewswire.com
BIIB
REGN
GILD
BTE
BROS
BFLY
BCTX
BCRX
BTAI
ALRS
CAPR
CRIS
CYCN
EXAS
FATE
GNTX
HRMY
INCY
IONS
KODK
LAKE
LULU
MRNA
NBIX
NTRA
OCGN
ORGN
PGEN
PLRX
RARE
RGNX
RXRX
SAVA
SGMO
SNOW
SRPT
STEM
TGTX
TLSA
TXG
VRTX
ZETA
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
globenewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
globenewswire.com
PLRX
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
prnewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
globenewswire.com
PLRX
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
globenewswire.com
PLRX
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
globenewswire.com
PLRX